Editas Medicine Inc (EDIT) Stock AnalysisEDITStock AnalysisEditas Medicine Inc

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Editas Medicine Inc is a good buy right now due to its recent performance and promising developments. The current price is $3.16, with a significant year-to-date change of +54.15%, indicating strong momentum. The RSI is at 54.6, suggesting the stock is neither overbought nor oversold, which is favorable for entry. Analyst targets suggest potential upside, with one firm setting a target of $15, indicating a potential upside of nearly 373% from the current price. The main risk is the company's high net loss of $18.23 million in Q2 2026, which reflects ongoing financial challenges.

8 analysts cover EDIT: 4 rate it Buy, 4 Hold and 0 Sell. The average price target is 3.78.